SEC Comment Letter 0000000000-22-012464 to IN8BIO, INC. (INAB) (CIK 0001740279) (INAB)
IN8BIO, INC. (INAB) (CIK 0001740279)
Date: Nov. 17, 2022 · CIK: 0001740279 · Accession: 0000000000-22-012464
AI Filing Summary & Sentiment
File numbers found in text: 333-268288
Letter
United States securities and exchange commission logo November 17, 2022 William Ho President and Chief Executive Officer IN8bio, Inc. 350 5th Avenue, Suite 5330 New York, New York 10118 Re:IN8bio, Inc. Registration Statement on Form S-3 Filed November 10, 2022 File No. 333-268288 Dear William Ho: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua A. Kaufman
Show Raw Text
United States securities and exchange commission logo
November 17, 2022
William Ho
President and Chief Executive Officer
IN8bio, Inc.
350 5th Avenue, Suite 5330
New York, New York 10118
Re:IN8bio, Inc.
Registration Statement on Form S-3
Filed November 10, 2022
File No. 333-268288
Dear William Ho:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua A. Kaufman